Comparing Frailty Indices for Risk Stratification in Urologic Oncology: Which Index to Choose?
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The revised Risk Analysis Index (RAI-Rev) better predicts mortality and non-home discharge after major urologic surgery compared to the modified Frailty Index (mFI). RAI-Rev shows greater utility for surgical risk stratification in these patients.
Area Of Science
- Urologic Oncology
- Geriatric Surgery
- Health Services Research
Background
- Frailty assessment is crucial for surgical risk stratification in major urologic oncologic surgery.
- The modified Frailty Index (mFI) and the revised Risk Analysis Index (RAI-Rev) are common frailty screening tools.
- Identifying the optimal tool is essential for accurate perioperative outcome prediction.
Purpose Of The Study
- To compare the predictive performance of mFI and RAI-Rev for 30-day perioperative outcomes.
- To determine the superior frailty screening tool for surgical risk stratification in major urologic oncologic surgery.
Main Methods
- Analysis of 101,739 patients undergoing major urologic surgery (2013-2017) from the NSQIP database.
- Multivariable logistic regression to assess the association of mFI and RAI-Rev with major complications, Clavien grade ≥4 complications, non-home discharge, readmission, and mortality.
- Receiver-operating characteristic (ROC) curve analysis and DeLong's test to compare the predictive abilities (C-statistics) of the two indices.
Main Results
- RAI-Rev demonstrated superior discriminatory ability for mortality (C-statistic: 0.688-0.798) and non-home discharge (C-statistic: 0.638-0.734) compared to mFI (C-statistic: 0.594-0.677 and 0.593-0.639, respectively).
- Both indices showed similar predictive performance for major perioperative complications (C-statistic: 0.531-0.607).
- Statistically significant differences favoring RAI-Rev were confirmed for mortality and non-home discharge (P < .001).
Conclusions
- RAI-Rev appears to be a more effective prognostic tool than mFI for patients undergoing major urologic surgery.
- These findings suggest RAI-Rev may offer greater utility in surgical risk stratification.
- Future prospective studies and clinical trials should consider these comparative results in their design.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...